The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Open accessAbstract
Akt is a central regulator of cell growth. Its activity can be negatively regulated by the phosphatase PHLPP that specifically dephosphorylates the hydrophobic motif of Akt (Ser473 in Akt1). However, how PHLPP is targeted to Akt is not clear. Here we show that FKBP51 (FK506-binding protein 51) acts as a scaffolding protein for Akt and PHLPP and promotes dephosphorylation of Akt. Furthermore, FKBP51 is downregulated in pancreatic cancer tissue samples and several cancer cell lines. Decreased FKBP51 expression in cancer cells results in hyperphosphorylation of Akt and decreased cell death following genotoxic stress. Overall, our findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications for cancer etiology and response to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 expression is decreased in several cancer cell lines and in pancreatic cancer tissue, and may correlate with increased Akt phosphorylation and reduced cell sensitivity to chemotherapeutic agents.”
From FKBP51 and FKBP52 in signaling and disease (2011) · cites this paper as [50]
In the citing paper
“A major advance in mechanistic understanding was the discovery that FKBP51 negatively regulates the activity of the cell growth regulator Akt, by serving as a scaffolding protein to recruit the phosphatase PHLPP [50].”
From FKBP51 and FKBP52 in signaling and disease (2011) · cites this paper as [50]
In the citing paper
“FKBP51 and FKBP52 likely have a similar activity; however, unlike Pin1, the FKBPs likely coordinate with Hsp90 to isomerize tau [50].”
From FKBP51 and FKBP52 in signaling and disease (2011) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Mechanism of activation of protein kinase B by insulin and IGF‐1.
Alessi, D. R., Andjelković, M., Caudwell, B., Cron, P. D., MORRICE, N. A., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,014
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874
Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797
A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase
Harding, M. W., Gałat, A., Uehling, D., & Schreiber, S. L. (1989) · Nature · doi:10.1038/341758a0 · Cited by 1,396
Mayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
Cited by
Sorted by citations
Items 101–200 of 727
Catanzaro, J. M., Sheshadri, N., Pan, J.-A., Sun, Y., Shi, C., Li, J., Powers, S., Crawford, H. C., & Zong, W. (2014) · Nature Communications · doi:10.1038/ncomms4729 · Cited by 88
Gupta, R., Malvi, P., Parajuli, K. R., Janoštiak, R., Bugide, S., Cai, G., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005156117 · Cited by 85
Acetaminophen-NAPQI Hepatotoxicity: A Cell Line Model System Genome-Wide Association Study
Moyer, A. M., Fridley, B. L., Jenkins, G. D., Batzler, A. J., Pelleymounter, L. L., Kalari, K. R., Ji, Y., Chai, Y., Nordgren, K. K. S., & Weinshilboum, R. M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq375 · Cited by 91
Self-citationRole of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation
Giovannetti, E., Wang, Q., Avan, A., Funel, N., Lagerweij, T., Lee, J., Caretti, V., van der Velde, A., Boggi, U., Wang, Y., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt346 · Cited by 82
Siolas, D., Vucic, E., Kurz, E., Hajdu, C. H., & Bar‐Sagi, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109578 · Cited by 82
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Ehsani, M., David, F. O., & Baniahmad, A. (2021) · Cancers · doi:10.3390/cancers13071534 · Cited by 83
Hirt, C., Booij, T. H., Grob, L., Simmler, P., Toussaint, N. C., Keller, D., Taube, D., Ludwig, V., Goryachkin, A., Pauli, C., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100095 · Cited by 92
Alvarellos, M. L., Lamba, J. K., Sangkuhl, K., Thorn, C. F., Wang, L., Klein, D. J., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000086 · Cited by 79
Self-citationXu, J., Lin, H. M., Li, G., Sun, Y., Chen, J., Shi, L., Cai, X., & Chang, C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.013 · Cited by 78
FKBPs and the Akt/mTOR pathway
Hausch, F., Kozany, C., Theodoropoulou, M., & Fabian, A. (2013) · Cell Cycle · doi:10.4161/cc.25508 · Cited by 84
Warfel, N. A., & Newton, A. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.318675 · Cited by 80
Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival
Fink, S. P., Myeroff, L. L., Kariv, R., Platzer, P., Xin, B., Mikkola, D. L., Lawrence, E., Morris, N. J., Nosrati, A., Willson, J. K. V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5921 · Cited by 80
Ghartey‐Kwansah, G., Li, Z., Feng, R., Wang, L., Zhou, X., Chen, F. Z., Xu, M., Jones, O. D., Mu, Y., Chen, S., et al. (2018) · BMC Developmental Biology · doi:10.1186/s12861-018-0167-3 · Cited by 77
Self-citationMangé, A., Coyaud, É., Desmetz, C., Laurent, E. M. N., Béganton, B., Coopman, P. J., Raught, B., & Solassol, J. (2019) · Theranostics · doi:10.7150/thno.35561 · Cited by 77
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells
Neault, M., Mallette, F. A., & Richard, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.068 · Cited by 78
Diverse structures, functions and uses of FK506 binding proteins
Bonner, J. M., & Boulianne, G. L. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.06.013 · Cited by 78
FKBP51 and the molecular chaperoning of metabolism
Smedlund, K., Sánchez, E. R., & Hinds, T. D. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.08.003 · Cited by 75
Focus on FKBP51: A molecular link between stress and metabolic disorders
Häusl, A. S., Balsevich, G., Gassen, N. C., & Schmidt, M. V. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.003 · Cited by 73
Jonckheere, N., & SEUNINGEN, I. V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1632-2 · Cited by 71
Tantai, J., Pan, X., Chen, Y., Shen, Y., & Ji, C. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04727-7 · Cited by 71
mTOR-Dependent Regulation of PHLPP Expression Controls the Rapamycin Sensitivity in Cancer Cells
Liu, J., Stevens, P. D., & Gao, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.183087 · Cited by 72
Epigenetics as a key link between psychosocial stress and aging: concepts, evidence, mechanisms
Zannas, A. S. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.4/azannas · Cited by 72
Zhou, Y., Chen, L., Zhang, Y., Hu, S., Dong, Z., Wu, M. J., Chen, Q., Zhuang, Z., & Du, X. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0113-2 · Cited by 69
Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression
Cheng, C., Tan, H., Wang, N., Chen, L., Meng, Z., Chen, Z., & Feng, Y. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.467 · Cited by 70
Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Wang, L., Mushiroda, T., Kubo, M., Costantino, J. P., Vogel, V. G., Paik, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0038 · Cited by 68
Self-citationHigh KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients
Xie, L., Dang, Y., Guo, J. J., Sun, X., Xie, T., Zhang, L., Yan, Z., Amin, H., & Guo, X. (2019) · Genes · doi:10.3390/genes10010036 · Cited by 68
CrossNorm: a novel normalization strategy for microarray data in cancers
Cheng, L., Lo, L.-Y., Tang, N. L. S., Wang, D., & Leung, K. (2016) · Scientific Reports · doi:10.1038/srep18898 · Cited by 67
Yu, Z., Yu, Z., Chen, Z., Yang, L., Ma, M., Lu, S., Wang, C., Teng, C., & Nie, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28670 · Cited by 64
FKBP family proteins as promising new biomarkers for cancer
Solassol, J., Mangé, A., & Maudelondé, T. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.012 · Cited by 67
High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer
Yang, C., Peng, P., Li, L., Shao, M., Zhao, J., Wang, L., Duan, F., Song, S., Wu, H., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep39044 · Cited by 67
Self-citationChen, J., Alduais, Y., Zhang, K., Zhu, X., & Chen, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16815 · Cited by 66
Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation
Cairns, J., Fridley, B. L., Jenkins, G. D., Zhuang, Y., Yu, J., & Wang, L. (2018) · EMBO Reports · doi:10.15252/embr.201744767 · Cited by 65
Self-citationMechanisms of brain glucocorticoid resistance in stress-induced psychopathologies
Merkulov, V. M., Merkulova, T. I., & Bondar, N. P. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917030142 · Cited by 65
Organization and function of the FKBP52 and FKBP51 genes
Cioffi, D. L., Hubler, T. R., & Scammell, J. G. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.013 · Cited by 64
HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Li, L., Tang, W., Wu, X., Karnak, D. M., Meng, X., Thompson, R. H., Hao, X., Li, Y., Qiao, X. T., Lin, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0621 · Cited by 67
Self-citationHuman Gastroenteropancreatic Expression of Melatonin and Its Receptors MT1 and MT2
Söderquist, F., Hellström, P. M., & Cunningham, J. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120195 · Cited by 65
Yang, W. S., Moon, H., Kim, H. S., Choi, E., Yu, M., Noh, D., & Lee, C. (2011) · Journal of Proteome Research · doi:10.1021/pr2008187 · Cited by 64
FK506 binding protein 51 integrates pathways of adaptation
Rein, T. (2016) · BioEssays · doi:10.1002/bies.201600050 · Cited by 67
Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition
Diedrich, B., Rigbolt, K. T. G., Röring, M., Herr, R., Kaeser-Pebernard, S., Gretzmeier, C., Murphy, R. F., Brummer, T., & Dengjel, J. (2017) · The EMBO Journal · doi:10.15252/embj.201694732 · Cited by 64
Huang, C., Chu, J., Zhu, X., Li, J., Huang, X., Cai, J., Zhao, W., & Yin, X.-Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.020 · Cited by 64
Pandey, R., Zhou, M., Islam, S., Chen, B., Barker, N. K., Langlais, P. R., Srivastava, A., Luo, M., Cooke, L. S., Weterings, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54545-9 · Cited by 63
FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Gassen, N. C., Hartmann, J., Zannas, A. S., Kretzschmar, A., Zschocke, J., Maccarrone, G., Hafner, K., Zellner, A., Kollmannsberger, L. K., Wagner, K. V., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.38 · Cited by 62
Klett, H., Füllgraf, H., Levit‐Zerdoun, E., Hussung, S., Kowar, S., Küsters, S., Bronsert, P., Werner, M., Wittel, U. A., Fritsch, R., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00108 · Cited by 62
Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Sang, W., Zhou, Y., Chen, H., Yu, C., Dai, L., Liu, Z., Chen, L., Fang, Y., Ma, P., Wu, X., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0584 · Cited by 61
Ellsworth, K. A., Moon, I., Eckloff, B. W., Fridley, B. L., Jenkins, G. D., Batzler, A. J., Biernacka, J. M., Abo, R., Brisbin, A. G., Ji, Y., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835dc133 · Cited by 63
Self-citationWille, C., Köhler, C., Armacki, M., Jamali, A., Gößele, U., Pfizenmaier, K., Seufferlein, T. T. W., & Eiseler, T. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-06-0334 · Cited by 60
FKBP51 Reciprocally Regulates GRα and PPARγ Activation via the Akt-p38 Pathway
Stechschulte, L. A., Hinds, T. D., Ghanem, S. S., Shou, W., Najjar, S. M., & Sánchez, E. R. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1023 · Cited by 59
Saito, R., Shirakawa, R., Nishiyama, H., Kobayashi, T., Kawato, M., Kanno, T., Nishizawa, K., Matsui, Y., Ohbayashi, T., Horiguchi, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.101 · Cited by 59
Musa, F., Alard, A., David‐West, G., Curtin, J. P., Blank, S. V., & Schneider, R. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0926 · Cited by 59
Yamaji, M., Ota, A., Wahiduzzaman, M., Karnan, S., Hyodo, T., Konishi, H., Tsuzuki, S., Hosokawa, Y., & Haniuda, M. (2017) · Cancer Medicine · doi:10.1002/cam4.1179 · Cited by 59
Li, H., Tian, Z., Qu, Y., Yang, Q., Guan, H., Shi, B., Ji, M., & Hou, P. (2018) · Oncogene · doi:10.1038/s41388-018-0434-6 · Cited by 57
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
Wu, X., Li, Y., Liu, X., Chen, C., Harrington, S. M., Cao, S., Xie, T., Pham, T. T., Mansfield, A. S., Yan, Y., et al. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e01039 · Cited by 57
Self-citationLiu, X., Yang, J.-W., Zeng, J., Chen, X., Gao, Y. P., Kui, X.-Y., Liu, X., Zhang, Y., Zhang, Y., & Pei, Z. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.853596 · Cited by 59
Malekpour, M., Shekouh, D., Safavinia, M. E., Shiralipour, S., Jalouli, M., Mortezanejad, S., Azarpira, N., & Ebrahimi, N. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1182345 · Cited by 71
Wang, J., Yang, S., He, P., Schetter, A. J., Gaedcke, J., Ghadimi, Β. M., Ried, T., Yfantis, H. G., Lee, D. H., Gaida, M. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0511 · Cited by 57
Smyth, L. J., Dahlström, E. H., Syreeni, A., Kerr, K., Kilner, J., Doyle, R., Brennan, E. P., Nair, V., Fermin, D., Nelson, R. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34963-6 · Cited by 57
Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer
Jahan, R., Ganguly, K., Smith, L. M., Atri, P., Carmicheal, J., Sheinin, Y. M., Rachagani, S., Natarajan, G., Brand, R. E., Macha, M. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.056 · Cited by 55
Glutamine deprivation triggers NAGK-dependent hexosamine salvage
Campbell, S., Mesaros, C., Izzo, L., Affronti, H., Noji, M., Schaffer, B. E., Tsang, T., Sun, K., Trefely, S., Kruijning, S., et al. (2021) · eLife · doi:10.7554/elife.62644 · Cited by 58
Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth
Qu, Y., Li, J., Cai, Q., & Liu, B. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0809-y · Cited by 54
Boonying, W., Joselin, A. P., Huang, E., Qu, D., Safarpour, F., Iyirhiaro, G. O., González, Y. R., Callaghan, S. M., Slack, R. S., Figeys, D., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14683 · Cited by 52
Manoochehri, M., Wu, Y., Giese, N. A., Strobel, O., Kutschmann, S., Haller, F., Hoheisel, J. D., Moskalev, E. A., Hackert, T., & Bauer, A. S. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12684 · Cited by 55
Deng, W., Vanderbilt, D. B., Lin, C., Martin, K. H., Brundage, K. M., & Ruppert, J. M. (2015) · Journal of Cell Science · doi:10.1242/jcs.162164 · Cited by 53
Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics
Liu, M., Goss, P. E., Ingle, J. N., Kubo, M., Furukawa, Y., Batzler, A. J., Jenkins, G. D., Carlson, E. E., Nakamura, Y., Schaid, D. J., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1147 · Cited by 53
Self-citationIdentification of microRNA–mRNA dysregulations in paroxysmal atrial fibrillation
Chiang, D. Y.-E., Zhang, M., Voigt, N., Alsina, K. M., Jakob, H. G., Martin, J. F., Dobrev, D., Wehrens, X. H. T., & Li, N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.01.075 · Cited by 53
FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
Hou, J., & Wang, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036252 · Cited by 52
Self-citationPAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis
Jun, S., Lee, S., Kim, H.-C., Ng, C., Schneider, A. M., Ji, H. L., Ying, H., Wang, H., DePinho, R. A., & Park, J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.026 · Cited by 76
Xue, J., Liu, Y., Wan, L., & Zhu, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.919953 · Cited by 53
Kim, S., Lahmy, R., Riha, C., Yang, C., Jakubison, B. L., van Niekerk, J., Staub, C., Wu, Y., Gates, K., Dong, D. S., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000328 · Cited by 48
FKBP51 regulation of AKT/protein kinase B phosphorylation
Wang, L. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.008 · Cited by 52
Self-citationFKBP51 Controls Cellular Adipogenesis through p38 Kinase-Mediated Phosphorylation of GRα and PPARγ
Stechschulte, L. A., Hinds, T. D., Khuder, S. S., Shou, W., Najjar, S. M., & Sánchez, E. R. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1022 · Cited by 52
Sivakumar, S., de Santiago, I., Chlon, L., & Markowetz, F. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002223 · Cited by 51
Tyagi, N., Deshmukh, S. K., Srivastava, S. K., Azim, S., Ahmad, A., AL-Ghadhban, A., Singh, A. P., Carter, J. E., Wang, B., & Singh, S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0219 · Cited by 51
Maurin, M. M., Ranjouri, M., Megino‐Luque, C., Newberg, J. Y., Du, D., Martin, K., Miner, R. E., Prater, M. S., Wee, D. K. B., Centeno, B. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44126-w · Cited by 53
Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells
Wang, M., Liu, Z. M., Li, X. C., Yao, Y. T., & Yin, Z. X. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000056 · Cited by 50
Hour, T., Chung, S., Kang, W.-Y., Lin, Y., Chuang, S.-J., Huang, A., Wu, W., Huang, S., Huang, C., & Pu, Y. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1275-x · Cited by 50
Mistafa, O., Ghalali, A., Kadekar, S., Högberg, J., & Stenius, U. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117093 · Cited by 51
Cervical Cancer Growth Is Regulated by a c-ABL–PLK1 Signaling Axis
Yang, X., Chen, G., Li, W., Peng, C., Zhu, Y., Yang, X., Li, T., Cao, C., & Pei, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1378 · Cited by 50
Self-citationLiu, B., Yang, H., Taher, L., Denz, A., Grützmann, R., Pilarsky, C. P., & Weber, G. F. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.03.003 · Cited by 50
Zhao, X., Liu, Z., Ren, Z., Wang, H., Wang, Z., Zhai, J., Cao, D., Lyu, S., Li, L., Lang, R., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173225 · Cited by 50
Self-citationYu, S., Yu, M., Bu, Z., He, P., & Feng, J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00193 · Cited by 51
Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis
Das, T. K., Dana, D., Paroly, S. S., Perumal, S. K., Singh, S., Jhun, H., Pendse, J., Cagan, R. L., Talele, T. T., & Kumar, S. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.34 · Cited by 50
MUC6 mucin expression inhibits tumor cell invasion
Leir, S., & Harris, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.07.021 · Cited by 49
InterAKTions with FKBPs - Mutational and Pharmacological Exploration
Fabian, A., März, A., Neimanis, S., Biondi, R. M., Kozany, C., & Hausch, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057508 · Cited by 51
Impact of intracellular ion channels on cancer development and progression
Peruzzo, R., Biasutto, L., Szabó, I., & Leanza, L. (2016) · European Biophysics Journal · doi:10.1007/s00249-016-1143-0 · Cited by 50
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma
Bydoun, M., Sterea, A. M., Liptay, H., Uzans, A., Huang, W., Rodrigues, G. J., Weaver, I. C. G., Gu, H., & Waisman, D. M. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12356 · Cited by 49
Huang, C., Zhang, X., Jiang, L., Zhang, L., Xiang, M., & Ren, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.05.005 · Cited by 50
Xie, C.-M., Tan, M., Lin, X.-T., Wu, D., Jiang, Y., Tan, Y., Li, H., Ma, Y., Xiong, X., & Sun, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.052 · Cited by 49
Ellsworth, K. A., Eckloff, B. W., Li, L., Moon, I., Fridley, B. L., Jenkins, G. D., Carlson, E., Brisbin, A. G., Abo, R., Bamlet, W. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070216 · Cited by 48
Self-citationZhang, G., He, P., Gaedcke, J., Ghadimi, Β. M., Ried, T., Yfantis, H. G., Lee, D. H., Hanna, N. N., Alexander, H. R., & Hussain, S. P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0362 · Cited by 48
Dean, M. E., & Johnson, J. L. (2020) · Cell Stress and Chaperones · doi:10.1007/s12192-020-01167-0 · Cited by 48
Evaluating the transcriptional fidelity of cancer models
Peng, D., Gleyzer, R., Tai, W.-H., Kumar, P., Bian, Q., Isaacs, B., da Rocha, E. L., Cai, S., DiNapoli, K. T., Huang, F. W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00888-w · Cited by 48
Kwon, M.-S., Kim, Y., Lee, S., Namkung, J., Yun, T., Yi, S. G., Han, S., Kang, M., Kim, S. W., Jang, J.-Y., et al. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s9-s4 · Cited by 47
Hosen, S. M. Z., Uddin, M. N., Xu, Z., Buckley, B. J., Perera, C. J., Pang, T., Mekapogu, A. R., Moni, M. A., Notta, F., Gallinger, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060957 · Cited by 50
HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation
Chia, L., Wang, B., Kim, J., Luo, L., Shuai, S., Herrera, I., Chen, S. Y., Li, L., Xian, L., Huso, T. H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci151601 · Cited by 52
Self-citationWen, Y., Stevens, P. D., Gasser, M. L., Andrei, R., & Gao, T. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00695-13 · Cited by 49
Matimba, A., Li, F., Livshits, A., Cartwright, C., Scully, S. S., Fridley, B. L., Jenkins, G. D., Batzler, A. J., Wang, L., Weinshilboum, R. M., et al. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.226 · Cited by 47
Self-citationHEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy
Liu, T., Fang, Y., Zhang, H., Deng, M., Gao, B., Niu, N., Yu, J., Lee, S., Kim, J.-J., Qin, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0671 · Cited by 46
Self-citationPI3K pathway in prostate cancer: All resistant roads lead to PI3K
Park, S., Kim, Y. S., Kim, D. Y., So, I., & Jeon, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.09.001 · Cited by 45
MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway
Wang, T., Chen, G., Ma, X., Yang, Y., Chen, Y., Peng, Y., Bai, Z., Zhang, Z., Pei, H., & Guo, W. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1326-6 · Cited by 47
Self-citationProline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer
Malla, R., Ashby, C. R., Narayanan, N. K., Narayanan, B. A., Faridi, J. S., & Tiwari, A. K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.041 · Cited by 46
Metadata
- Authors
- Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z., & Wang, L.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Lou, Zhenkun
- Wang, Liewei
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 16
- Issue
- 3
- Pages
- 259-266
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2755578
- OpenAlex
- W1996667997
- Cited by
- 709
- References
- 27
- Citations by year
- 2026: 23 · 2025: 26 · 2024: 31 · 2023: 44 · 2022: 59 · 2021: 73 · 2020: 63 · 2019: 53 · 2018: 39 · 2017: 48 · 2016: 43 · 2015: 47 · 2014: 48 · 2013: 37 · 2012: 24
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA102701, P20CA102701, K22CA130828, P50CA102701, R01CA130996, R01CA129344, R01CA138461)
- National Institute of General Medical Sciences (U01GM061388, U19GM061388, GM61388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- FKBP51, Akt, PHLPP, Akt dephosphorylation, scaffold proteins, pancreatic cancer, chemotherapy response, genotoxic stress, cell death
- MeSH terms
- Docetaxel, Tacrolimus Binding Protein 5, Antimetabolites, Antineoplastic, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Cell Line, Cytarabine, Drug Therapy, Humans, Kidney, Neoplasms, Nuclear Proteins, Pancreatic Neoplasms, Phosphoprotein Phosphatases, Paclitaxel, Tacrolimus Binding Proteins, Taxoids, Cell Line, Tumor, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
